Avanos Medical Q3 EPS Forecast Lowered by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS) – Stock analysts at Zacks Research cut their Q3 2025 earnings per share estimates for Avanos Medical in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.41 for the quarter, down from their previous estimate of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Down 1.1 %

Shares of AVNS opened at $19.16 on Monday. The business’s 50 day simple moving average is $21.64 and its 200-day simple moving average is $21.56. Avanos Medical has a 1 year low of $17.39 and a 1 year high of $25.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The stock has a market capitalization of $880.59 million, a price-to-earnings ratio of 56.97 and a beta of 0.92.

Hedge Funds Weigh In On Avanos Medical

Several institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Avanos Medical during the third quarter valued at about $42,000. KBC Group NV raised its stake in shares of Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock worth $68,000 after acquiring an additional 1,095 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Avanos Medical during the second quarter valued at approximately $70,000. Intech Investment Management LLC acquired a new stake in Avanos Medical in the third quarter valued at approximately $207,000. Finally, Atom Investors LP purchased a new position in Avanos Medical in the third quarter worth $210,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.